Director Ghiath M. Sukhtian buys $5 million of Outlook Therapeutics, Inc. (OTLK)

About this page

WallStPal explains public SEC filings and congressional stock trade reports in plain English. Nothing is for sale; the site is free and supported by ads.

How to read it

Form 4

The form a company insider (officer, director or owner of more than 10%) must file with the SEC within two business days of buying or selling the company's shares.

13F

A quarterly list of U.S. stocks held by an investment manager with more than $100 million, filed within 45 days after each quarter ends.

STOCK Act

A 2012 law that requires members of Congress to report stock trades by themselves, a spouse or a dependent child within 45 days.

A real example

In January 2016, when bank stocks were falling, JPMorgan Chase CEO Jamie Dimon bought 500,000 JPMorgan shares with his own money, worth about $26 million. His Form 4 made the purchase public within days, and investors read it as a strong sign of confidence.

Explain it like I'm 13

We read the long, boring forms that grown-ups file with the government and tell you what they say in normal words.

Data from public SEC filings and congressional reports. Information, not investment advice. Check every number against the filing linked on the page.

Director Ghiath M. Sukhtian buys $5 million of Outlook Therapeutics, Inc. (OTLK)

Ghiath M. Sukhtian, director, bought $5 million of stock. WallStPal Score 62.

WallStPal ScoreHow much this purchase says, from 0 to 100. How it works

Ghiath M. Sukhtian, director of Outlook Therapeutics, Inc., bought 8,539,709 shares on the open market on May 28, 2026 at an average of $0.59 a share, for a total of $5 million. The purchase was reported to the SEC on Form 4 on June 1, 2026.

It raised their holding by 63%, to 22,092,068 shares.

Outlook Therapeutics, Inc. stock was up 78% over the 13 weeks before the purchase.

3 other insiders also bought at least $10,000 of OTLK within 30 days, which makes this a cluster buy.

In the 12 months up to this filing, Outlook Therapeutics, Inc. insiders reported 5 open-market purchases and 0 sales.

WallStPal Score: 62 out of 100, because of raised their holding by 63%; a large purchase; 3 other insiders also bought.

What happened next: after 1 month the stock was up 169.9% (171.2 points better than the S&P 500); after 3 months the stock was up 11% (9.8 points better than the S&P 500). Based on weekly prices from the week of the purchase.

Source: SEC Form 4 filing ↗. This story was written automatically from the filing and weekly price data. Information, not investment advice.

Examples

Big insider purchases have made news before. In January 2016, with bank stocks falling, JPMorgan Chase CEO Jamie Dimon bought 500,000 JPMorgan shares, about $26 million of his own money, and the purchase was widely reported as a sign of confidence.

Explain it like I'm 13

Ghiath M. Sukhtian helps run Outlook Therapeutics, Inc.. Spending $5 million of their own money on the company's stock is like a coach buying a big stack of tickets to their own team's games: it suggests they think the team will do well. It is not a promise, and insiders can be wrong.

More: all OTLK insider trades · Ghiath M. Sukhtian's track record